4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
49 citations
,
October 2023 in “Journal of Dermatological Science” 
1 citations
,
July 2023 in “International Journal of Molecular Sciences” This study found that a hypoxic microenvironment enhanced the proliferation and pluripotency of adipose mesenchymal stem cells, promoting hair follicle formation and upregulating specific growth factors in Arbas Cashmere goats.
February 2023 in “Lasers in Medical Science” 8 citations
,
October 2022 in “Dermatologic Therapy” In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.
July 2022 in “Dermatologic Therapy” This study reported that both topical methotrexate 1% gel and minoxidil 5% gel were effective in treating localized alopecia areata, with no significant differences in efficacy between the two treatments.
January 2022 in “Przegla̧d dermatologiczny” This article reviews the use of minoxidil for alopecia treatment and finds that low-dose oral or topical forms can be effective with manageable side effects, although some patients may still experience them.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
23 citations
,
November 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology” This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.
4 citations
,
May 2019 in “PubMed” This study reported that the expression of sulfotransferase enzymes in hair follicles remained stable during treatment with topical minoxidil, indicating consistent metabolic activity throughout the treatment period.
148 citations
,
December 2018 in “Journal of autoimmunity” This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.
16 citations
,
January 2018 in “International Journal of Trichology” In this study, minoxidil significantly downregulated interleukin-1 alpha expression in human keratinocyte cells, suggesting an anti-inflammatory effect that may be a mechanism of action in treating alopecia.
21 citations
,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
15 citations
,
May 2017 in “Journal of Dermatological Treatment” In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.
62 citations
,
October 2016 in “Dermatologic Therapy” This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.
152 citations
,
April 2012 in “Recent Patents on Inflammation & Allergy Drug Discovery” This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.
29 citations
,
March 2010 in “Journal of Dermatological Science” This study found that Wnt3a increased beta-catenin signaling and upregulated specific genes in cultured human dermal papilla cells, enhancing their response to PGE2 and potentially aiding hair growth.
102 citations
,
February 2008 in “The FASEB Journal” This study found that human hair follicles express ATP-sensitive potassium channels, suggesting that minoxidil acts on these channels and that drugs targeting them may treat hair disorders.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
185 citations
,
August 2005 in “Autoimmunity Reviews” This review discusses alopecia areata as a model for studying tissue-directed autoimmune diseases and reports no new clinical findings.
149 citations
,
March 2004 in “Journal of Dermatological Science” This study found that minoxidil stimulates hair follicle growth by promoting dermal papilla cell survival and activating ERK and Akt pathways, which leads to increased proliferation and reduced cell death.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
520 citations
,
February 2001 in “Journal of Clinical Investigation” This study found that VEGF significantly enhances perifollicular vascularization during the hair growth phase, accelerating hair regrowth and increasing follicle and hair size, while its inhibition retards hair growth.
41 citations
,
November 1993 in “Journal of The American Academy of Dermatology” This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.
33 citations
,
July 1992 in “Journal of Investigative Dermatology” Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.
46 citations
,
June 1990 in “Archives of dermatology” In this study, combination therapy with 5% minoxidil and 0.5% anthralin showed some cosmetic improvement in 11% of patients with severe treatment-resistant alopecia areata, with hair regrowth starting by week 12.
36 citations
,
March 1989 in “Cleveland Clinic Journal of Medicine” 3% topical minoxidil effectively treats extensive alopecia areata.
121 citations
,
March 1989 in “Journal of Investigative Dermatology” Minoxidil can help grow hair in mice by making cells grow and improving hair quality. More research needed.
7 citations
,
October 1988 in “Clinics in Dermatology” Minoxidil may help hair regrowth in alopecia areata by affecting T-cells.
23 citations
,
March 1988 in “Biochemical Pharmacology” This study found that minoxidil inhibited prostacyclin production in various endothelial and smooth muscle cells in culture without affecting the synthesis of other cyclooxygenase products.
13 citations
,
December 1987 in “British Journal of Dermatology” This study suggests that increased T cell blastogenesis may predict a positive response to topical 5% minoxidil treatment in patients with severe alopecia areata.
26 citations
,
March 1987 in “Journal of the American Academy of Dermatology” This study suggests that topical minoxidil may aid hair regrowth in alopecia areata through synergistic effects on follicular epithelium and lymphocyte-mediated immunological responses, alongside its vasodilatory properties.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
54 citations
,
March 1987 in “Journal of The American Academy of Dermatology” In this study, 3% topical minoxidil showed some efficacy in hair regrowth for patients with extensive alopecia areata, especially those with less than total scalp hair loss, but did not lead to complete remission.
31 citations
,
January 1987 in “Dermatology” This study reports that topical minoxidil led to normalization of hair follicle characteristics in 36 of 47 severe alopecia areata patients, and indicated a shift in T cell populations, suggesting potential immunomodulatory effects.
34 citations
,
January 1987 in “Dermatology” In this study, topical minoxidil was found to be an effective, safe, and easy treatment for individuals with alopecia areata affecting 25–99% of the scalp, but less effective for total scalp hair loss.
54 citations
,
February 1986 in “Archives of Dermatology” This study found that 5% topical minoxidil solution led to greater hair regrowth in severe alopecia areata patients compared to 1% minoxidil, although most regrowth was not cosmetically acceptable.
17 citations
,
March 1985 in “Acta Dermato Venereologica” This study found that 1% topical minoxidil led to an increase in terminal hair growth in some individuals with alopecia areata, but only one case showed cosmetically satisfying results.
18 citations
,
March 1984 in “BMJ” Minoxidil helps hair regrowth in alopecia, but more research needed.
